CellART segments and labels cells in one pass across four spatial transcriptomics platforms
CellART, an open-source Python tool, segments cells and assigns cell types in one pass on data from four high-resolution spatial transcriptomics platforms. Its MIT licence lets labs that run those steps separately test the swap on their own slides.
Reality
- Evidence40
- Adoption
- Not scored
- Hype gap+25
- Incentives
- Not scored
- Confidence50
Researchers open a 6-million-cell map of prefrontal gene activity from nearly 1,500 brains
Researchers measured gene activity in over 6 million prefrontal cortex cells from nearly 1,500 donors and published it openly in eight studies. Each sample is a postmortem snapshot, so the map can link cell changes to a disease without showing which came first.
Reality
- Evidence50
- Adoption
- Not scored
- Hype gap+20
- Incentives
- Not scored
- Confidence45
High glucose drove inflammation in human kidney organoids that have no immune cells
In Stem Cell Reports, a team led by Benjamin Freedman reports that stem-cell-derived kidney organoids, which contain no immune cells and no blood vessels, shed podocytes in high-glucose media, and that blocking MIF or TNF-alpha protected them. The pattern resembles what patient biopsies show.
Reality
- Evidence58
- Adoption
- Not scored
- Hype gap+12
- Incentives55
- Confidence55
Whole gene cohorts switch in the cell body as axons reach the spinal midline
Brown University researchers sequenced more than 12,000 rodent commissural neurons at four developmental stages and found the cell body swapping guidance receptor programs as axons reached the spinal midline. The profiling stops short of manipulating those genes.
Reality
- Evidence60
- Adoption
- Not scored
- Hype gap+30
- Incentives45
- Confidence58
Researchers report in Nature that mouse skull bone marrow holds germinal-centre-like lymphoid structures that respond to CNS antigens and help drive anti-tumour immunity.
Perspective Coverage
3 publishers
- Builder
- Builder 51%
- Operator
- Operator 27%
- Investor
- Investor 22%
Reality
- Evidence72
- Adoption12
- Hype gap+28
- Incentives55
- Confidence68